Remove 2014 Remove FDA Remove Safety Remove Specialization
article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

Out of the seven biologics approved to treat moderate to severe CD in adults, only the anti-TNFαs, Remicade (infliximab), and Humira (adalimumab), have been approved for paediatric patients, with Humira receiving the most recent approval in 2014.

Medical 59
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. In 2020, the FDA-approved indication was expanded to include those patients who suffer from cataplexy.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

Founded in 1935 by Chiesi’s grandfather of the same name, Chiesi Group focuses on respiratory conditions, special care, and on rare diseases, including lysosomal storage disorders and rare haematological and ophthalmological diseases. “An But rare diseases are a particularly important and challenging focus area.